Skip to main content
SpringerLink
Log in

Apolipoprotein E knockout mice as a model of behavioral dysfunction

  • Editorial Article
  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72, 1283–1293.

    Article  PubMed  CAS  Google Scholar 

  • Brenneman D. E., Spong C. Y., Hauser J. M., Abebe D., Pinhasov A., Golian T., and Gozes I. (2004) Protective peptides that are orally active and mechanistically non-chiral. J. Pharmacol. Exp. Ther. March 8, 2004 [Epub ahead of print].

  • Chen Y., Lomnitski L., Michaelson D. M., and Shohami E. (1997) Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 80, 1255–1262.

    Article  PubMed  CAS  Google Scholar 

  • Fisher A., Brandeis R., Chapman S., Pittel Z., and Michaelson D. M. (1998) M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J. Neurochem. 70, 1991–1997.

    Article  PubMed  CAS  Google Scholar 

  • Genis I., Fisher A., and Michaelson D. M. (1999) Sitespecific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J. Neurochem. 72, 206–213.

    Article  PubMed  CAS  Google Scholar 

  • Gordon I., Grauer E., Genis I., Sehayek E., and Michaelson D. M. (1995) Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci. Lett. 199, 1–4.

    Article  PubMed  CAS  Google Scholar 

  • Gozes I., Bachar M., Bardea A., Davidson A., Rubinraut S., Fridkin M., and Giladi E. (1997) Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implication for early treatment of Alzheimers disease. J. Neurobiol. 33, 329–342.

    Article  PubMed  CAS  Google Scholar 

  • Gozes I. and Brenneman D. E. (2000) A new concept in neuroprotection. J. Molec. Neurosci. 14, 61–68.

    Article  PubMed  CAS  Google Scholar 

  • Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D. E., and Spier A.D. (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Molec. Neurosci. 20, 315–322.

    Article  PubMed  CAS  Google Scholar 

  • Gozes I., Perl O., Giladi E., Davidson A., Ashur-Fabian O., Rubinraut S., and Fridkin M. (1999) Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc. Natl. Acad. Sci. USA 96, 4143–4148.

    Article  PubMed  CAS  Google Scholar 

  • Grootendorst J., de Kloet E. R., Dalm S., and Oitzl M. S. (2001) Reversal of cognitive deficit of apolipoprotein E knockout mice after repeated exposure to a common environmental experience. Neuroscience 108, 237–247.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Sackler Faculty of Medicine, Tel Aviv University, 69978, Tel Aviv, Israel

    Illana Gozes

Authors
  1. Illana Gozes
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Preclinical studies related to NAP were supported in part by the Institute for the Study of Aging (ISOA), Allon Therapeutics, Inc., NIA, and NICHD. Professor Illana Gozes serves as the Chief Scientific Officer of Allon Therapeutics, Inc. This short editorial is by no means a comprehensive literature review. Rather, it highlights aspects of the ApoE knockout mice as an animal model capturing facets of Alzheimer’s disease that can be used for the assessments of candidate protective molecules.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gozes, I. Apolipoprotein E knockout mice as a model of behavioral dysfunction. J Mol Neurosci 23, 149–150 (2004). https://doi.org/10.1385/JMN:23:3:149

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/JMN:23:3:149

Search

Navigation